The results showed that the expression of Nrf2 in newly diagnosed and relapsed and refractory AML patients was higher than that in normal donors and complete remission groups (P < 0.05, Fig. 1A, B). This evidence concerns the gene NFE2L2 and acute myeloid leukemia.